Celgene

This study tests two experimental drug combinations for adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (IDH-mutant AML) who cannot tolerate intensive chemotherapy. Participants receive either one of two oral targeted pills (AG-120 or AG-221) plus…

This study tests a treatment called JCAR017, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with a type of slow-growing lymphoma (follicular or marginal zone) that has come back or not responded to prior treatments. The…

This study tests whether a new combination of drugs (iberdomide, daratumumab, and dexamethasone) works better than the current standard treatment for people whose multiple myeloma has returned or stopped responding to earlier therapy. About 939 adults with 1–2 prior treatments ar…

This study tests whether adding a one-time CAR T-cell treatment (idecabtagene vicleucel) to standard lenalidomide maintenance therapy can better control multiple myeloma in adults who had a stem cell transplant but didn't get a full response. About 79 participants will receive ei…

This study tests an experimental pill, CC-99282, in people with non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The main goals are to check the drug's safety and find the best dose, both when used alone and with other lymphoma medicines. About…

This study tests a new drug called CC-220, alone or with other medicines, in people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see if the drug helps shrink tumors. About 466 adults with relapsed or newly diagnosed myeloma are taking par…

This study tests whether adding the experimental drug golcadomide to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated high-risk large B-cell lymphoma. About 850 adults will take part, and researchers will compare how long the cancer st…

This study tests a new drug, golcadomide, combined with rituximab in 90 people with newly diagnosed advanced follicular lymphoma. The goal is to see if the combination can make the cancer disappear completely on scans. Participants must not have had prior treatment for this lymph…

This study monitors the safety of lenalidomide in over 900 adults newly diagnosed with multiple myeloma who cannot have a stem cell transplant. Researchers compare heart-related side effects between patients taking lenalidomide and those on other standard treatments. Participants…